{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.6","value":"297"},{"groupId":"OG001","spread":"18.7","value":"113"},{"groupId":"OG002","spread":"29.5","value":"184"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"AUCu was defined as free-drug area under the concentration-time curve from time zero to infinity (extrapolated), calculated as (AUC0-last + Ct/λz) \\* Fu, where: Ct = the last observed nonzero concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.","id":"OG000","title":"Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function"},{"description":"Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision.","id":"OG001","title":"Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function"},{"description":"Participants with severe hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision.","id":"OG002","title":"Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis was defined as all participants in the monotherapy part who received at least 1 dose of selinexor and had at least 1 post-dose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of selinexor (e.g., vomited at or before 6 hours; wrong dose administered; prohibited concomitant medication). Here 'Overall Number of Participants Analyzed' signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8","title":"Monotherapy: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in Plasma","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}